Characteristics of HER2-Positive Breast Cancer according to HER2 2+/Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate the characteristics of HER2-positive breast cancer according to HER2 low (2+) or high (3+) classification using immunohistochemistry (IHC). Methods: Data were collected from 205 HER2-positive breast cancer patients in the final assay, regardless of IHC or in situ hybridization (ISH). We thus classified patients into two groups: HER2 2+/low and HER2 3+/high based on the IHC assay. We subsequently compared the clinical and pathological characteristics between groups. Results: The median patient age was 49 years in the HER2 2+/low group and 53 years in the HER2 3+/high group. We observed a significantly lower Allred score for estrogen receptor (ER) and progesterone receptor (PR) (0-6) (p<0.001), less lymphatic invasion (LI), (p=0.010), neural invasion (p=0.041), higher Ki-67 (p=0.001), and lower Bcl-2 (p<0.001) in the HER2 3+/high group than in the HER2 2+/low group. Lymph node recurrence was more frequently observed in the HER2 2+/low group than in HER2 3+/high group (p=0.005). Disease-free survival (DFS) was better in the HER2 3+/high group than in the HER2 2+/low group (p=0.028), but there were no significant differences in overall survival between the groups (p=0.233). Conclusion: The HER2 3+/high group was associated with lower ER and PR expression, less LI, higher Ki-67, and lower Bcl-2 than that in HER2 2+/low group in HER2-positive breast cancer. Furthermore, compared to the HER2 2+/low group, the HER2 3+/high group had an improved DFS.
Abstract
Purpose: To investigate the characteristics of HER2-positive breast cancer according to HER2 low (2+) or high (3+) classification using immunohistochemistry (IHC). Methods: Data were collected from 205 HER2-positive breast cancer patients in the final assay, regardless of IHC or in situ hybridization (ISH). We thus classified patients into two groups: HER2 2+/low and HER2 3+/high based on the IHC assay. We subsequently compared the clinical and pathological characteristics between groups. Results: The median patient age was 49 years in the HER2 2+/low group and 53 years in the HER2 3+/high group. We observed a significantly lower Allred score for estrogen receptor (ER) and progesterone receptor (PR) (0-6) (p<0.001), less lymphatic invasion (LI), (p=0.010), neural invasion (p=0.041), higher Ki-67 (p=0.001), and lower Bcl-2 (p<0.001) in the HER2 3+/high group than in the HER2 2+/low group. Lymph node recurrence was more frequently observed in the HER2 2+/low group than in HER2 3+/high group (p=0.005). Disease-free survival (DFS) was better in the HER2 3+/high group than in the HER2 2+/low group (p=0.028), but there were no significant differences in overall survival between the groups (p=0.233). Conclusion: The HER2 3+/high group was associated with lower ER and PR expression, less LI, higher Ki-67, and lower Bcl-2 than that in HER2 2+/low group in HER2-positive breast cancer. Furthermore, compared to the HER2 2+/low group, the HER2 3+/high group had an improved DFS.
참고문헌 (28)
- Hudis CA, "Trastuzumab—mechanism of action and use in clinical practice", N Engl J Med, 357, pp.30~51 (2007)
- Meric-Bernstam F, "Advances in targeting human epi-dermal growth factor receptor-2 signaling for cancer therapy", Clin Cancer Res, 12, pp.6326~6330 (2006)
- Slamon DJ, "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu onco-gene, 1987, pp.235, 177~182
- Slamon DJ, "Studies of the HER-2", neu proto-oncogene in human breast and ovarian cancer, 1989, pp.244, 707~712
- Gabos Z, "Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diag-nosed breast cancer", J Clin Oncol, 24, pp.5658~5663 (2006)
- Pernas S, "HER2-positive breast cancer : new therapeu-tic frontiers and overcoming resistance", Ther Adv Med Oncol, 11, pp.1~16 (2019)
- Ihemelandu CU, "Treatment and survival outcome for molecular breast cancer subtypes in black women", Ann Surg, 247, pp.463~469 (2008)
- Houssami N, "Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy", Eur J Cancer, 48, pp.3342~3354 (2012)
- Wang H, "The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes : a SEER based study", Oncotarget, 8, pp.26368~26379 (2017)
- Hanna WM, "Comparative analysis of human epidermal growth factor receptor 2testing in breast cancer according to 2007 and 2013 American soci-ety of clinical oncology", college of American pathologists guideline recommendations, 2017, pp.35, 3039~3045
- Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer : American society of clini-cal oncology", college of American pathologists clinical practice guideline update, 2013, pp.31, 3997~
- Liu ZH, "Impact of the updated 2018 ASCO", CAP guidelines on HER2 FISH testing in in-vasive breast cancer : a retrospective study of HER2 FISH results of 2233 cases, 2019, pp.175, 51~57
- Marchiò C, "Evolving concepts in HER2 evaluation in breast cancer : het-erogeneity, HER2-low carcinomas and beyond", Semin Cancer Biol, 72, pp.123~135 (2021)
- Nuciforo P, "High HER2 protein levels correlate with increased sur-vival in breast cancer patients treated with anti-HER2 therapy", Mol Oncol, 10, pp.138~147 (2016)
- Han-Sung Kim, "Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer", Journal of Breast Cancer, 15(4), pp.401~406 (2012), 한국유방암학회[DOI]
- 박경미, "Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer", Journal of Breast Cancer, 14(4), pp.276~282 (2011), 한국유방암학회
- Buckley NE, "Quantification of HER2 heterogeneity in breast cancer-impli-cations for identification of sub-dominant clones for personalized treatment", Sci Rep, 6, pp.23383~ (2016)
- Lee HJ, "Clinicopath-ologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab", Am J Clin Pathol, 14, pp.570~578 (2015)
- Allison KH, "Frequency of HER2 hetero-geneity by fluorescence in situ hybridization according to CAP ex-pert panel recommendations : time for a new look at how to report heterogeneity", Am J Clin Pathol, 136, pp.864~871 (2011)
- Vance GH, "Genetic heterogeneity in HER2 testing in breast cancer : panel summary and guidelines", Arch Pathol Lab Med, 133, pp.611~612 (2009)
- Beca F, "Intratumor heterogeneity in breast cancer", Adv Exp Med Biol, 882, pp.169~189 (2016)
- Arpino G, "Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family : molecular mechanism and clinical implications for endocrine ther-apy resistance", Endocr Rev, 29, pp.217~233 (2008)
- Garcia-Becerra R, "Mechanisms of re-sistance to endocrine therapy in breast cancer : focus on signaling pathways, miRNAs and genetically based resistance", Int J Mol Sci, 14, pp.108~145 (2013)
- Rexer BN, "Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer : mechanisms and clinical implications", Crit Rev Oncog, 17, pp.1~16 (2012)
- Shou J, "Mechanisms of tamoxifen resistance : increased estrogen recep-tor-HER2", neu cross-talk in ER, J Natl Cancer Inst, pp.2004, 96[DOI]
- Lousberg L, "Resistance to therapy in es-trogen receptor positive and human epidermal growth factor 2 pos-itive breast cancers : progress with latest therapeutic strategies", Ther Adv Med Oncol, 8, pp.429~449 (2016)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Kurbel S, "Distri-bution of Ki-67 values within HER2 & ER", PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology, 2017, pp.17, 231~